Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 17/20 | 0.55 |
| ▸ | CYBB | P04839 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1303163 | 0.91 | NOX4 (0.59) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL13394146 | 0.90 | NOX4 (0.51) | NOX4CYBBCYP3A4NOX1MEN1 | |
| SCHEMBL1301864 | 0.87 | NOX4 (0.59) | NOX4CYBBCYP3A4NOX1TNKS | |
| SCHEMBL1302625 | 0.82 | NOX4 (0.55) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL1302610 | 0.81 | NOX4 (0.81) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL1303115 | 0.81 | NOX4 (0.66) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL2212833 | 0.80 | NOX4 (0.61) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL8471746 | 0.79 | NOX4 (0.53) | NOX4CYBBCYP3A4NOX1MEN1 | |
| SCHEMBL1302661 | 0.78 | NOX4 (0.53) | NOX4CYBBCYP3A4NOX1 | |
| SCHEMBL1303036 | 0.77 | NOX4 (0.58) | NOX4CYBBCYP3A4NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-11-03 | — | — | US | disclosed |
| EP-2166010-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYO TEX SA (CH) | 2010-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885CYP3A4 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.